Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0B7OY
|
|||
Former ID |
DNCL003684
|
|||
Drug Name |
CT 327
|
|||
Indication | Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Phase 2 | [1] | |
Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2 | [2] | ||
Company |
Creabilis Therapeutics
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tropomyosin-related kinase A (TrkA) | Target Info | Inhibitor | [3] |
KEGG Pathway | MAPK signaling pathway | |||
Endocytosis | ||||
Apoptosis | ||||
Neurotrophin signaling pathway | ||||
Inflammatory mediator regulation of TRP channels | ||||
Pathways in cancer | ||||
Transcriptional misregulation in cancer | ||||
Thyroid cancer | ||||
Central carbon metabolism in cancer | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | |||
Reactome | Frs2-mediated activation | |||
ARMS-mediated activation | ||||
NGF-independant TRKA activation | ||||
PI3K/AKT activation | ||||
WikiPathways | MAPK Signaling Pathway | |||
BDNF signaling pathway | ||||
Integrated Pancreatic Cancer Pathway | ||||
NGF signalling via TRKA from the plasma membrane |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | ClinicalTrials.gov (NCT01808157) A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis. U.S. National Institutes of Health. | |||
REF 3 | Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.